Herpes zoster is produced when the varicella·zoster virus is activated and infects the sensitive nerves. The incidence of Herpes zóster increases with age and immunosuppression, and does not vary with sex.
In this case control study, matched by sex, it was determined the possible association between some risk factors and the development of Herpes zoster, using McNemar's method. The study population was 88 cases with their respective controls, 39 males and 49 females. People with fifty years or older where 4.4 times more likely to have a virus reactivation (CI 95%, 1.98-10.8); the possible association between malignancy and Herpes zoster was due to chance. Immunosuppressive treatment predisposed 3.3 times the development of this patology (CI 95%, 1.25-9.53); and finally, the AlDS patients were 18 times more likely to have a virus reactivation (CI 95%, 2.18).
Downloads
Download data is not yet available.
References
Whitley R: Varicelia-zóster virus, en Principies and practice of infectious diseases, ed por Mandell G,
Bennett J, Dolin R, 4ed,. New York, Churchili Livingstone, 1995, pp 1345 -1351.
Safrin S: Herpes simplex and varicella zóster virus infections in HIV-infected individuals, en Textbook of AIDS medicine, ed por Merigan T, Barlett J, Borlognesi D, 2ed, Pennsylvania, Wiliiams & Williams, 1999, pp 396 - 402.
Donahue J, Choo P, Manson J, Platt R: The incidence of Herpes-zóster. Arch Intern Med 1995; 155: 1605-1609.
Ragozzino M, Melton L, Kurland L, Chu C, Peny H: Population-based study of herpes-zóster and its sequelae. Medicine 1982; 61: 310 - 316.
Departamento de Investigaciones Epidemiológicas, basado en los informesepidemiológicos de las regiones de salud. Panamá, 1998.
Whitley R: Varicella-zóster virus infections, en Harrison's principies of internal medicine, ed por Fauci A, Braunwald E, Isselbacher K, Wilson J, Martín J, et al, 14ed, New York, The McGraw-Hill Companies Inc, 1998, pp 1086-1088.
Galil K, Choo P, Donahue J, Platt R: The sequelae of herpes-zóster. Arch Intern Med 1997; 157: 1209-1213.
Schlesselman J: Case - Control Studies: Design, Conduct, Analysis, New York, Oxford University Press, 1982, pp 145-160.
Schimpff S, Serpi9k A, Staler B, et al: Varicella-zóster infection in patients with caneer. Ann Intern Med 1972; 76: 241 - 254.
Weller T: Varicella and herpes zóster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 1983; 309: 1362-1368.
Burgoon C, Burgoon J, Baldridge G: The natural history of herpes-zóster. JAMA 1957; 164: 265-269.
Straus S, Ostrove J, Inchauspe G: Varicella-zóster virus infections: biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108: 221-237.
Rusthoven J, Ahlgren P, Elhakim T, et al: Varicellazóster infection in adult cancer patients. Arch Intern Med 1988; 148: 1561-1566.
Alison F, Phillip P, Thomas W: Infections in the cancer patients, en Cancer principies & practice of oncology ed por De Vita V Jr, Hellman S, Rosenberg S, 5ed, Philadelphia, Lippincott-Raven, 1997, pp 2691-2692.
Buchbinder S, Katz M, Hessol N, Liu J, et eols: Herpeszóster and human inmunodeficiency virus infection. J Infect Dis 1992; 166: 1153-115.
Moss A, Bacchetti P, Osmond D: Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow-up of the San Francisco General Hospital cohort. Br Med J 1988; 296: 745-750.
